Genome & Company (KOSDAQ:314130)
South Korea · Delayed Price · Currency is KRW 6,400.00
-350.00 (-5.19%)
At close: Feb 26, 2026
Genome & Company Market Cap
Genome & Company has a market cap or net worth of 221.92 billion as of February 27, 2026. Its market cap has increased by 173.28% in one year.
Market Cap
221.92B
Enterprise Value
211.05B
Revenue
25.95B
Ranking
n/a
PE Ratio
n/a
Stock Price
6,400.00
Market Cap Chart
Since December 26, 2018, Genome & Company's market cap has increased from 71.88B to 221.92B, an increase of 208.74%. That is a compound annual growth rate of 17.01%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 27, 2026 | 221.92B | -6.91% |
| Dec 30, 2025 | 238.38B | 179.77% |
| Dec 30, 2024 | 85.21B | -51.64% |
| Dec 28, 2023 | 176.21B | -28.34% |
| Dec 29, 2022 | 245.90B | -47.55% |
| Dec 30, 2021 | 468.83B | -55.28% |
| Dec 30, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 28, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 26, 2018 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| NIBEC | 364.28B |
| ABION | 284.27B |
| ISU Abxis | 219.48B |
| QuadMedicine | 217.24B |
| Bio Solution | 216.34B |
| Prestige Biologics | 214.60B |
| Kangstem Biotech | 205.98B |
| Ensol Biosciences | 194.80B |